7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin mac-1 and blocks adhesion to fibrinogen and ICAM-1

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 3, 1997, Pages 528-535

  Simon, Daniel I ^a   Xu, Hui ^a   Ortlepp, Susan ^b   Rogers, Campbell ^a,c   Rao, Navaneetha K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UCB PHARMA   (Belgium)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

cellular adhesion; integrins; monoclonal antibody; monocytes; restenosis

Indexed keywords

ABCIXIMAB; CD11B ANTIGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CELL ADHESION; CHO CELL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; INFLAMMATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; TISSUE REPAIR;

EID: 0030934389     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.3.528     Document Type: Article

References (16)

1. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12: 616-623.
2. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van de Brand M, Reiber JH, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty - a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77: 361-371.
3. Kuntz RE, Gibson M, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting, and directional atherectomy. J Am Coll Cardiol. 1993;21:15-25.
4. Waller BF. Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease. Cardiol Clin. 1989;7: 749-770.
5. Chesebro JA, Lam JYT, Badimon, Fuster V. Restenosis after arterial angioplasty: a hemorheologic response to injury. Am J Cardiol. 1987;60:10B-16B.
6. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty: potential biologic determinants and the role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
7. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
8. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
9. Schwartz RS. Animal models of human coronary restenosis. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders; 1994:365-381.
10. Pompa J, Califf RM, Topol El. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
11. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
12. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet. 1994;343:881-886.
13. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
14. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987; 48:549-554.
15. Charo IF, Fitzgerald LA, Steiner B, Rail SC Jr, Bekeart LS, Phillips DR. Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci USA. 1986;83:8351-8355.
16. Altieri DC, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol. 1988;141: 2656-2660.